Should men get a PSA test to screen for prostate cancer, and when?

by Ross Krasnow, MD, Urologic Oncologist
September 19, 2017

Prostate cancer is the most common cancer in men, with one in seven men in the United States projected to get the disease in their lifetime. And the District of Columbia has the second highest prostate cancer incidence rate in the country behind only Louisiana, with 123 out of 100,000 men diagnosed with the disease in a given year.

One of the best screening tools we have for this disease is the prostate-specific antigen (PSA) test. While there’s no doubt this simple blood test has saved lives over the years, it’s not perfect. There’s been a lot of debate over who should be screened and when—and whether men should be screened at all. Even national health organizations differ slightly on their PSA testing guidelines.

PSA testing is not a one-size-fits-all approach to prostate cancer screening. The key is to have an honest conversation about the potential benefits and harms for each man based on his specific risk factors.

LISTEN: Dr. Krasnow discusses PSA testing, including what men may expect from future prostate cancer screening, further on this Medical Intel podcast.

Benefits and risks of PSA testing

Prostate-specific antigen is a protein made in the prostate gland and present in semen. A small amount of PSA enters the bloodstream, but high levels in a man’s blood can indicate prostate cancer. After the PSA test’s introduction in the late 1980s, deaths related to prostate cancer began to decrease. In fact, mortality rates fell nearly 40 percent between the early 1990s and 2008.

This was a huge win in our fight against prostate cancer. However, there also have been some negatives associated with the test, the biggest being its 15 percent false-positive rate. A false positive is when the test detects cancer that is not present.

This means 15 in 100 men who get an elevated PSA test result do not actually have prostate cancer. Unfortunately, to confirm this, they’ve likely undergone an unnecessary biopsy. While generally safe, biopsies can cause complications, such as bleeding or infection and can induce unnecessary stress for the patient.

PSA testing also can increase the risk of overtreatment. Most diagnosed prostate cancers are low-grade, which means the abnormal cells are unlikely to impact a man’s life in any way. Prostate cancer is a slow-growing cancer, taking 10 to 15 years to progress and even longer to cause death. These tumors may only need close monitoring over the years, also known as active surveillance, and not treatment.

Do the potential benefits of PSA testing outweigh the potential harms? It depends on the person. Some of my patients who have received a false positive were relieved to know their cancer status for sure. Others, while relieved, continued to worry about their elevated PSA level as we monitored them over the following years. And still others were frustrated that they had to go through the biopsy process, which, while not painful, is awkward and uncomfortable.

What studies and guidelines say about PSA testing

Actor Ben Stiller made waves in 2016 with a blog post titled “The Prostate Cancer Test That Saved My Life.” In the article, he attributed surviving prostate cancer to having a PSA test at age 46—earlier than most guidelines would recommend—despite having no indicators that he was at increased risk for the disease.

He wrote: “If (my doctor) had waited (to get me a PSA test), as the American Cancer Society recommends, until I was 50, I would not have known I had a growing tumor until two years after I got treated. If he had followed the U.S. Preventive Services Task Force guidelines, I would have never gotten tested at all, and not have known I had cancer until it was way too late to treat successfully.”

If you’re looking to various health organizations for guidance on when you should have a PSA test, you may be confused by the differing recommendations. And these recommendations also may change over time. For example, the U.S. Preventive Services Task Force slightly revised its guidelines since Ben Stiller had his PSA test based on new evidence and studies.

Here is what some health organizations currently recommend:

  • American Cancer Society: The organization recommends that men at average risk for prostate cancer begin discussing screening with their doctors at age 50. Men at increased risk should consider screening at age 45.
  • American Urological Association: The organization recommends that doctors begin discussing screening at age 40 to 54 for men at high risk, 55 to 69 for men at average risk, and 70 and older for some men in excellent health with a 10- to 15-year life expectancy.
  • U.S. Preventive Services Task Force: The group in 2017 recommended that while the PSA test should not be used routinely, physicians should discuss the benefits and harms with men age 55 to 69. It recommends against PSA screening for men 70 and older. This is in contrast to its 2012 guidelines that recommended against PSA screening in men without prostate cancer symptoms.

So what’s a man supposed to do? The answer lies in the common theme to these recommendations: a discussion between doctor and patient.

How I advise men about screening for prostate cancer

I once treated a man in his 40s who was exhibiting signs of benign prostatic hyperplasia, a condition in which the prostate is enlarged. We decided to do a PSA test, despite most guidelines recommending against PSA testing for a man younger than 50 with no increased risk factors for prostate cancer. The test showed elevated PSA levels, but a traditional biopsy only found very low-grade cancer.

This didn’t make sense considering his high PSA levels. We had a long conversation about how to proceed, and we decided to do advanced testing. An MRI-guided biopsy that is increasingly being used to detect prostate cancer revealed a high-grade prostate cancer that, left unchecked, would have been lethal.

PSA test guidelines aren’t hard and fast rules—as my patient and Ben Stiller would attest to. The key is an open, honest conversation in which the patient and doctor come to a decision together.

Related reading: Shared decision-making: It’s no longer “doctor knows best”

For a man at average risk for prostate cancer, the discussion may center more on the potential benefits and harms of a PSA test. However, the conversation may take on a more urgent tone if the man has factors that put him at increased risk for prostate cancer. These can include:

  • Family history: Having a first-degree relative, such as a father or brother, who had the disease.
  • Genetic mutations: We’re continually learning more about how certain gene mutations can increase a man’s risk for prostate cancer. This includes mutations of the BRCA1 and BRCA2 genes, which are more commonly associated with breast and ovarian cancers.
  • Race: African-Americans have double the incidence of prostate cancer compared with white men, and their risk of dying from the disease is two to three times higher.

A man’s age also should be taken into effect. Because prostate cancer grows so slowly, there’s little benefit to screening older men whose life expectancies are less than 10 to 15 years. When I see a patient who is 70 or older and has been referred to me for a PSA test, I usually advise against it unless they are extremely healthy for their age.

I think as medical professionals, we’re doing a better job of screening smarter and being more selective in who gets a PSA test. But discussion is the key.

Request an appointment to talk to a doctor about your prostate cancer risk and screening options.

Request an Appointment

Category: Healthy Living, Medical Intel     Tags: Dr. Ross Krasnowprostate cancerpsa levelspsa test